KEYLearning Hub
Optimising the care of your mNSCLC patients with KEYTRUDA® (pembrolizumab) plus chemotherapy
KEYLearning Hub
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
Welcome to the KEYLearning Hub, a series of digestible peer-to-peer videos on the day-to-day management of patients with metastatic non-small cell lung cancer (mNSCLC) treated with KEYTRUDA® (pembrolizumab) plus chemotherapy.
- KEYTRUDA as monotherapy is indicated for the first-line treatment of metastatic non-small cell lung carcinoma in adults whose tumours express PD-L1 with a ≥50% tumour proportion score (TPS) with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) positive tumour mutations
- KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of metastatic non-squamous non-small cell lung carcinoma in adults whose tumours have no EGFR or ALK positive mutations
- KEYTRUDA, in combination with carboplatin and either paclitaxel or nab-paclitaxel, is indicated for the first-line treatment of metastatic squamous non-small cell lung carcinoma in adults
- KEYTRUDA as monotherapy is indicated for the treatment of locally advanced or metastatic non-small cell lung carcinoma in adults whose tumours express PD-L1 with a ≥1% TPS and who have received at least one prior chemotherapy regimen. Patients with EGFR or ALK positive tumour mutations should also have received targeted therapy before receiving KEYTRUDA
Listen to experienced clinical nurse specialists, oncologists, and specialist registrars share their real-world experience of patient management by discussing treatment journeys from initiation to end of treatment.
Here’s what to expect from starting your KEYLearning journey…
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
Explore the hub…
CPD Certified
Optimising Patient Care: Hear from your peers
Learn how KEYTRUDA works and how to identify immune-mediated adverse events in KEYTRUDA plus chemotherapy patients.
CPD Certified
Immuno-oncology (IO) treatment in first-line metastatic non-small cell lung carcinoma (mNSCLC) – a focus on KEYTRUDA (pembrolizumab) in patients with a PD-L1 expression of <1% through case studies
Learn about the day-to-day management of patients with mNSCLC treated with KEYTRUDA® (pembrolizumab) plus chemotherapy.
CPD certified
Identification and management of colitis and pneumonitis in IO plus chemotherapy metastatic NSCLC patients – focus on KEYTRUDA (pembrolizumab)
Learn about how colitis and pneumonitis can be easily misdiagnosed as other conditions in lung cancer patients.
Supporting documentation
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website
